HER2 Cancer Gene

HER2-associated Lung Cancer: Mutations and Amplifications Result in Different Cancers


Two distinct causes of HER2 activation in lung cancer were demonstrated in a recent study. These findings imply that HER2-positive lung cancer may need different targeted therapies to combat these related but possibly distinct diseases.

HER2 inhibition shows promise in HER2-positive non-small cell lung cancer


Human epidermal growth factor receptor 2 (HER2) mutations may offer an important treatment target in a subset of patients with non-small cell lung cancer.

Guidelines issued for HER2-negative breast cancer

Guidelines issued for HER2-negative breast cancer

Evidence-based recommendations have been developed for chemotherapy and targeted therapy for women with HER2-negative advanced breast cancer.

HER2 testing may incorrectly classify some women with breast cancer


A recent study of HER2 testing in a large cohort of women with breast cancer found important limitations in testing methods.

Guideline update leaves out novel tests in breast cancer

Guideline update leaves out novel tests in breast cancer


Massimo Cristofanilli, MD, talks about why the updated ASCO/CAP guidelines should support the use of mRNA and DNA microarray assays.

Breast cancer drug proposed for bladder cancer patients


Researchers have found amplification of HER2—a known driver of some breast cancers—in a type of bladder cancer called micropapillary urothelial carcinoma (MPUC).

ASCO/CAP update advice on HER2 testing in breast cancer


All persons with invasive breast cancer (early stage or recurrence) should undergo testing for human epidermal growth factor receptor 2 (HER2), and at least one tumor sample should be tested for either HER2 protein expression or HER2 gene amplification.

<i>HER2</i> gene abnormalities found in a variety of advanced cancers


Irregularities in the expression of the HER2 growth-factor gene have been found in 14 different advanced solid tumors.

Anti-HER2 treatments may benefit some patients with lung cancer


A new retrospective study suggests that anti-HER2 treatments have anti-cancer effects in a small subset of patients with advanced non-small cell lung cancer who harbor specific mutations in the HER2 protein.

Some breast cancers may respond to anti-androgen drug


Newly approved for prostate cancer, enzalutamide may be useful as a therapeutic agent in breast cancer that evades other treatments.

Annual report highlights 2012 cancer advances

The American Society of Clinical Oncology has released a nearly 100-page report detailing the year's most significant developments in cancer.

Drug combo shows promise in triple-negative breast cancer

Combining a PI3K inhibitor with a PARP inhibitor may be an effective therapy for triple-negative breast cancer, researchers have determined.

HER2 breast cancer may respond to PARP inhibitors

PARP inhibitors may be a novel treatment strategy for women with HER2-positive breast cancers, researchers have found.

Vaccine used in early breast cancer shows good immunity response


Many women with early breast cancer experienced a sustained immune response after immunization with a vaccine that fights HER2, and this may reduce their risk for more invasive cancer.

Trastuzumab, chemotherapy can prolong life despite CNS metastases

Study results indicate that women with HER2-positive metastatic breast cancer should receive trastuzumab and, potentially, chemotherapy, even if the cancer has spread to the brain.

New assay reduces false negatives in breast cancer ER status

A method employing fluorescent detection appears to be more adept than conventional immunohistochemistry in identifying estrogen receptor (ER)-positive breast cancers.

FDA approves test that identifies Herceptin candidates

A new genetic test that will help health care providers determine whether women with breast cancer are eligible for treatment with trastuzumab (Herceptin) has been approved by the FDA.

New or recurrent tumor status irrelevant in breast cancer relapse

Both new and recurring cancers will differ significantly from original tumors, and treatment should be tailored to the specific qualities of the second tumor.

Anticancer properties of olives

The anticancer properties of olives have been highlighted in two research papers.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs